부산대학교 도서관

Aim: To analyze VKORC1, CYP2C9 and CYP4F2 polymorphisms in relation to the main outcomes in the first stages of acenocoumarol therapy. Patients & methods: Nine hundred and forty one patients who had started therapy and in whom time to stable dosage, time to over-anticoagulation and adverse events occurred during 3 first months were retrospectively analyzed. Results: VKORC1 AA patients needed fewer days to reach stable dosage (p = 0.017). International normalized ratio [INR] at 72 h, and VKORC1 and CYP2C9 genotypes conditioned INR values [greater than]2.5 (p [less than] 0.001, p = 0.002 and p [less than] 0.001, respectively), whereas CYP4F2 T carriers had a low risk of the same outcome (p = 0.009). In regards to combined genotypes, CYP4F2 had a significant effect on over-anticoagulation at the beginning of therapy except for the VKORC1 AA and CYP2C9*3 combination. Conclusion: In addition to VKORC1 and CYP2C9, CYP4F2 gene has a slight but significant role in reaching INR [greater than]2.5 during the first weeks of acenocoumarol therapy. Original submitted 22 July 2013; Revision submitted 14 November 2013
Author(s): Juan Jose Cerezo-Manchado [sup.aff1] , Vanessa Roldan [sup.aff1] , Mario Rosafalco [sup.aff2] , Ana Isabel Anton [sup.aff1] , Ana Belen Arroyo [sup.aff1] , Nuria Garcia-Barbera [sup.aff1] , Ana Belen [...]